Sign up to save your podcasts
Or
Share Thailand's MedTech Shift: Pure Global on the New Change-Notification Landmines.
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Thailand's MedTech Shift: Pure Global on the New Change-Notification Landmines.
This week, we dive into a sudden regulatory shift from Thailand's FDA. A new guideline on medical device change notifications was issued on April 16th, and it's more than just a minor update. It redraws the lines between minor and major device changes, creating new compliance risks for foreign manufacturers.
We break down how this seemingly small adjustment can lead to significant market access delays and what it signals about the future of post-market surveillance in the ASEAN region.
**Case Study:** Your company is rolling out a critical cybersecurity patch for your medical software already sold in Thailand. Previously a simple notification, the new rule could reclassify this as a major change, forcing you to pull the product from the market for months pending a full regulatory review. How do you protect your patients and your business from this unexpected roadblock?
**Key Takeaways:**
* What specific changes did Thailand's new guideline introduce on April 16th?
* How can a change in notification policy create immediate compliance landmines?
* Why is your definition of a "minor change" probably now wrong for the Thai market?
* Could this update force a delay in the launch of your product's next generation?
* Is this a sign of a larger trend towards stricter post-market surveillance in ASEAN?
* What are the three essential questions you must ask your local regulatory partner today?
* How can you turn this new regulatory hurdle into a competitive advantage?
At Pure Global, we offer end-to-end regulatory consulting solutions for MedTech and IVD companies. We combine local expertise with advanced AI and data tools to streamline global market access and ensure you are always ahead of critical changes like this. For inquiries, contact us at [email protected] or visit https://pureglobal.com/.
View all episodes
By Ran ChenThis week, we dive into a sudden regulatory shift from Thailand's FDA. A new guideline on medical device change notifications was issued on April 16th, and it's more than just a minor update. It redraws the lines between minor and major device changes, creating new compliance risks for foreign manufacturers.
We break down how this seemingly small adjustment can lead to significant market access delays and what it signals about the future of post-market surveillance in the ASEAN region.
**Case Study:** Your company is rolling out a critical cybersecurity patch for your medical software already sold in Thailand. Previously a simple notification, the new rule could reclassify this as a major change, forcing you to pull the product from the market for months pending a full regulatory review. How do you protect your patients and your business from this unexpected roadblock?
**Key Takeaways:**
* What specific changes did Thailand's new guideline introduce on April 16th?
* How can a change in notification policy create immediate compliance landmines?
* Why is your definition of a "minor change" probably now wrong for the Thai market?
* Could this update force a delay in the launch of your product's next generation?
* Is this a sign of a larger trend towards stricter post-market surveillance in ASEAN?
* What are the three essential questions you must ask your local regulatory partner today?
* How can you turn this new regulatory hurdle into a competitive advantage?
At Pure Global, we offer end-to-end regulatory consulting solutions for MedTech and IVD companies. We combine local expertise with advanced AI and data tools to streamline global market access and ensure you are always ahead of critical changes like this. For inquiries, contact us at [email protected] or visit https://pureglobal.com/.